2019
DOI: 10.3389/fphar.2019.00066
|View full text |Cite|
|
Sign up to set email alerts
|

Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma

Abstract: The beneficial effects of H2S-release and of COXs-inhibition have been exploited in the design of novel anti-inflammatory drugs, the H2S-releasing non-steroidal anti-inflammatory drugs (H2S-NSAIDs), showing promising potential for chemoprevention in cancers. Here, we evaluated the efficacy of a new H2S-releasing derivative of naproxen, named naproxen-4-hydroxybenzodithioate (naproxen-HBTA), in reducing metastatic melanoma features, both in vitro and in vivo. The novel H2S donor has been prepared following a sy… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
22
0
3

Year Published

2019
2019
2024
2024

Publication Types

Select...
8
1

Relationship

3
6

Authors

Journals

citations
Cited by 28 publications
(26 citation statements)
references
References 41 publications
1
22
0
3
Order By: Relevance
“…Furthermore, oral administration of ATB‐346 (43 μmol·kg −1 ) to mice resulted in significant growth delay of the melanoma tumours (up to 70%), without affecting body weight (De Cicco et al, ). In a recently published study from the same group, Ercolano et al () show that another H 2 S‐releasing naproxen derivative, naproxen‐4‐hydroxybenzodithioate (naproxen‐HBTA; at 10 and 30 μM; Figure ), induced caspase 3‐mediated apoptosis and inhibited human melanoma cell proliferation, migration, invasion, and colony formation in vitro. In addition, the authors also show the beneficial effects, in vivo, of this H 2 S‐releasing naproxen derivative, as the daily oral treatment of mice with 14.5 mg·kg −1 of naproxen‐HBTA resulted in significant suppression of melanoma growth and progression.…”
Section: H2s and Skin Diseasesmentioning
confidence: 98%
“…Furthermore, oral administration of ATB‐346 (43 μmol·kg −1 ) to mice resulted in significant growth delay of the melanoma tumours (up to 70%), without affecting body weight (De Cicco et al, ). In a recently published study from the same group, Ercolano et al () show that another H 2 S‐releasing naproxen derivative, naproxen‐4‐hydroxybenzodithioate (naproxen‐HBTA; at 10 and 30 μM; Figure ), induced caspase 3‐mediated apoptosis and inhibited human melanoma cell proliferation, migration, invasion, and colony formation in vitro. In addition, the authors also show the beneficial effects, in vivo, of this H 2 S‐releasing naproxen derivative, as the daily oral treatment of mice with 14.5 mg·kg −1 of naproxen‐HBTA resulted in significant suppression of melanoma growth and progression.…”
Section: H2s and Skin Diseasesmentioning
confidence: 98%
“…A similar investigation on in vitro models of macrophages and in vivo fat-fed apoE − / − mice was carried out also with a particular class of H 2 S-donor, i.e. the H 2 S-donors hybrids [78] , [79] , [80] , [81] . These compounds were synthesized on the basis of previous experience on the NO-donor hybrids, in order to confer the positive effects of the gasotransmitter to selected native molecules.…”
Section: Hydrogen Sulfide and Atherosclerosis-related Endothelial Dysmentioning
confidence: 99%
“…Thus, in order to obtain effective H 2 S donors with controllable release rates, a series of N-(benzoylthio)benzamides [ 49 ], acyl perthiols [ 50 , 51 ], arylthioamides [ 52 ], 1,2,4-thiadiazolidin-3,5-diones [ 53 ], iminothioethers [ 54 ], mercaptopyruvate [ 55 ], dithioates [ 56 ], isothiocyanate [ 57 , 58 ], and thiocarbamates [ 59 ] were developed and evaluated for their H 2 S-releasing properties.…”
Section: H 2 S Donorsmentioning
confidence: 99%